PIK3CB and non-small cell lung carcinoma: The excellent anti-tumor effect shows that ISP-I provide a new therapeutic option targeting to NSCLC patients carrying KEAP1 mutation through excessive ROS accumulation and play dual roles as a PI3K/AKT pathway inhibitor simultaneously.